During the past decade, the advancement of EGFR-TKIs revolutionarily transformed the landscape of treatment and prognosis in advanced lung adenocarcinoma, but BM remains a therapeutically challenging issue [24]. The gene discussed is EGFR; the disease is lung adenocarcinoma.